The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Advances in prostate cancer in the last 10 years and a glimpse to the future
Advances in prostate cancer in the last 10 years and a glimpse to the future
Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in...
Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )
12 Jun 2020
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurre...
Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )
12 Jun 2020
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based thera...
Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )
12 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma ( Dr Katie Kelley - University of California San Francisco, San Francisco, USA )
12 Jun 2020
COVID-19 and breast cancer: How should we treat our patients?
Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
COVID-19 and breast cancer: How should we treat our patients? ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )
12 Jun 2020
Reducing damage to swallowing muscles during radiotherapy for head and neck canc...
Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK
Reducing damage to swallowing muscles during radiotherapy for head and neck cancers ( Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK )
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )
12 Jun 2020
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and n...
Dr Naomi Kiyota - Kobe University, Kobe, Japan
3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck ( Dr Naomi Kiyota - Kobe University, Kobe, Japan )
12 Jun 2020
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...
Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA
Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )
12 Jun 2020
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer
Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA
METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )
12 Jun 2020

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation